Novelix Pharmaceuticals Ltd - 536565 - Announcement Under Regulation 30 (LODR) - Intimation Regarding The Execution Of An Agreement With GMBU
E.V., Halle (Saale), Germany.
Novelix Pharmaceuticals signed an agreement with GMBU e.V., Germany, for the commercial scale-up of Astaxanthin production. This will take place at the company's research facilities in Hyderabad, India, after successful pilot scale production.
Jun 03 2026 15:45:14
Novelix Pharmaceuticals Ltd - 536565 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Novelix Pharmaceuticals Limited's promoter, Vupparapalli Chandrasekhar Reddy, increased their stake by 1.47 percentage points to 8.92%. This was achieved by converting 5.6 lakh warrants into equity shares through a preferential allotment on May 29, 2026.
Jun 03 2026 10:33:04
Novelix Pharmaceuticals Ltd - 536565 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Trimurthi's promoter group acquired 9.50 lakh equity shares through the conversion of warrants issued via preferential allotment on May 29, 2026. This transaction increased their absolute shareholding.
Jun 03 2026 10:30:47
Novelix Pharmaceuticals Ltd - 536565 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
Novelix Pharmaceuticals' promoter group increased its aggregate shareholding by 2.77%. This was achieved by acquiring 31.3 lakh equity shares through allotment following the conversion of warrants and a preferential offer.
Jun 02 2026 19:37:01
Novelix Pharmaceuticals Ltd - 536565 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Novelix Pharmaceuticals' promoter and promoter group entities, Srinidhi Fine-Chemicals LLP and Narahari Belide, were allotted 9.50 lakh equity shares through the conversion of warrants on a preferential basis on May 29, 2026. Their total holding stands at 36.42%.
Jun 02 2026 10:50:37
Novelix Pharmaceuticals Ltd - 536565 - Board Meeting Intimation for Prior Intimation Of Board Meeting To Be Held On Thursday, 04Th June, 2026 Pursuant To Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Trimurthi's Board of Directors will convene on June 04, 2026, to evaluate and potentially approve a preferential issue of securities. The meeting will also address the adoption of the EGM notice and setting its date for shareholder approval.
Jun 01 2026 20:41:20
Novelix Pharmaceuticals Ltd - 536565 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Promoter Vupparapalli Chandrasekhar Reddy of Trimurthi increased their direct equity holding by converting 5.6 lakh warrants into shares. This conversion on May 29, 2026, raised their stake to 8.92% from 7.45%.
Jun 01 2026 18:17:37
Novelix Pharmaceuticals Ltd - 536565 - Announcement under Regulation 30 (LODR)-Allotment
Novelix Pharmaceuticals Limited allotted 2.81 million equity shares of Rs.10 face value each at an issue price of Rs.20 per share upon conversion of warrants. This allotment was primarily to promoter and promoter group entities, increasing the company's paid-up equity capital.
May 30 2026 16:21:11
Novelix Pharmaceuticals Ltd - 536565 - Board Meeting Intimation for Prior Intimation Of Board Meeting To Be Held On Friday, 29Th May, 2026.
Trimurthi board will meet on May 29, 2026, to consider and approve Q4 FY26 financial results and audited statements. The agenda also includes a preferential issue of securities and allotment of equity shares.
May 25 2026 20:04:39
Read More